Member Info for benbenbenben

He mentioned the stability and the shelf life because this performance data is required for the CE marking. The CE mark will essentially have three main components:

- Clinical evaluation (done)
- Manufacturing process/control data (presumably very near completion is GAD tech-transfer is now happening to BBI, etc)
- Stability data for final product (This is what they are completing on an "accelerated" program already underway)

As they are manufacturing the first commercial batches already, clearly they are confident there will not be issues.

So given where we are and the presumption they have already completed much of the reporting required for the CE mark, for once it is likely (IMHO) that there isn't long to wait!

You can't short Avacta on IG; you can only go long.

They close the markets when they are over exposed by the cumulative trades - looking at IG's market data, the number of long's has increased lately and Avacta is often high on the 'popular shares' list.

So In a nutshell, lots of people are betting it's going up!

On the plus side, he calls for LFT's to be reviewed by using live patient samples to compare performance with PCR - which is precisely what our CV has done!

https://twitter.com/OmegaDiagnostic/status/1387041631950360583?s=20

It's part of a thread - it relates to the LFT tweet above

Ah, Purdah would make a lot sense as a reason for it to not be announced already..

Entangled - worth also noting that ABDX's financial year starts in June

Nice one, Muck!

Olly - If you read through the documents which accompany the tender for the DPS framework (we are attempting to join through Porton Down) you will see the PHE/DHSC say they will consider alternative validation protocols if they equivocate (in their view) the PD process.

Therefore there should be little issue for us, as our study starts at the end point of theirs (3B?), using live patient samples to generate performance data.

and John Bell has millions of $ in Roche shares - he used to sit on their board...

Dan - we are in a trading range; we aren't going 'down and down' forever, we will find a floor - likely where we are now - and I would expect us to bounce from here next week.

While I am disappointed we haven't broken out of (and held above) the top of our range (275-ish) off the back of the excellent test performance, I'm confident we will in the very near future.

Looking at the price action another way, we also broke all time highs this week and got close to them again on more than one occasion - point being that there is clearly interest in the stock and buyers willing to pay higher prices for it.

While the fast money has left us in the belief news is some weeks away, I am quietly confident we will be hearing again from the company sooner than we think.

Thanks for that Celtics, I feel I learnt something from your post!

Mark - riddle me this: if you’ve been waiting since “last summer”, when the price was below £2, and it’s now April, and the price is £2.40, how are you a “lamb to the slaughter”? How have you managed to be losing money here?!

Poor attempt!

I think you're probably right Timster.

I wouldn't want to be out for long though; Al's been talking about overseas OEM's for months - he made it clear today they had been waiting for CV before committing capacity.

I would be quite surprised if they'd been in discussions all this time and didn't have contracts already pretty much agreed and ready to sign. Presumably they would also be anxious to begin the tech-transfer/lead-in to production ASAP and so wouldn't hang about.

Therefore I would speculate we could hear something soon - perhaps even next week...

Now we have CV, I think news will really flow!

Could be huge!

This is going to be bigger than I think any of us have imagined...

Looking for US manufacturing atm!!

From his last statement I would expect news on overseas manufacturing pretty soon...

It detects the S/A variant!

That's always been the plan - he's stated that throughout development.

hahaha I'd forgotten about 137!!